.

Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Drug patents and clinical trials in dozens of countries

► See Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Cipla
Merck
Johnson and Johnson
US Department of Justice
Mallinckrodt
Cerilliant
AstraZeneca
Boehringer Ingelheim
Federal Trade Commission
Healthtrust

Generated: June 24, 2017

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 040224

« Back to Dashboard
NDA 040224 describes CHLORPROMAZINE HYDROCHLORIDE, which is a drug marketed by Lederle, Purepac Pharm, Abraxis Pharm, Abbott, Alpharma Us Pharms, Usl Pharma, Pharm Assoc, West-ward Pharms Int, Cycle Pharms Ltd, Wockhardt, Vangard, Sandoz, Pvt Form, Kv Pharm, Ivax Sub Teva Pharms, Watson Labs, Actavis Mid Atlantic, Marsam Pharms Llc, West Ward, and Wyeth Ayerst, and is included in fifty-four NDAs. It is available from thirteen suppliers. Additional details are available on the CHLORPROMAZINE HYDROCHLORIDE profile page.

The generic ingredient in CHLORPROMAZINE HYDROCHLORIDE is chlorpromazine hydrochloride. There are eighteen drug master file entries for this compound. Thirteen suppliers are listed for this compound. Additional details are available on the chlorpromazine hydrochloride profile page.

Summary for NDA: 040224

Tradename:
1
Applicant:
1
Ingredient:
1
Patents:1
Therapeutic Class:Antiemetics
Antipsychotics
Formulation / Manufacturing:see details

Summary for product number 001

Active Rx/OTC/Discontinued:DISCNDosage:CONCENTRATE;ORALStrength100MG/ML
Approval Date:Jan 26, 1999TE:RLD:No


Complete Access Available with Subscription
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Merck
Queensland Health
Harvard Business School
Teva
Fish and Richardson
Mallinckrodt
Novartis
Julphar
Chinese Patent Office
Citi

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot